CAPRICOR THERAPEUTICS, INC.
Capricor Therapeutics, Inc. (CAPR)
Overview
Capricor Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing cell and exosome-based therapeutics for rare diseases with significant unmet medical need. Listed on Nasdaq under CAPR, the company has no marketed products and is not yet profitable, but carries a market capitalization of roughly $527 million as of September 2026 on the strength of its lead program, deramiocel, a cardiosphere-derived cell (CDC) therapy for Duchenne muscular dystrophy (DMD) currently under FDA review. Capricor has funded its pipeline with approximately $600 million raised cumulatively through equity financings, government and foundation grants (including NIH and the California Institute for Regenerative Medicine), and strategic collaboration payments, and reported roughly 231 employees following a 2025 expansion of its San Diego manufacturing footprint.
What They Do & How They Make Money
Capricor does not yet generate commercial product revenue; instead, its money today comes from grant funding and upfront/milestone payments under collaboration and distribution agreements, most notably with Nippon Shinyaku. Under that partnership, Capricor licensed U.S. rights to deramiocel in exchange for $30 million upfront, a $20 million milestone tied to BLA submission, up to $80 million upon FDA approval, and sales-based milestones reaching as high as $605 million plus a 30–50% U.S. revenue share; a parallel Japan agreement provides $12 million upfront and up to $89 million in additional milestones plus a double-digit royalty, and a term sheet for Europe outlines up to $20 million upfront and $715 million in potential milestones. The long-term business model is to commercialize deramiocel — first for DMD skeletal and cardiac muscle complications, and later for Becker muscular dystrophy — while building out a second platform, StealthX, an engineered exosome technology currently in a Phase 1 trial as a SARS-CoV-2 vaccine candidate and being explored for broader therapeutic delivery applications. Success hinges on converting deramiocel's positive Phase 3 (HOPE-3) trial data into FDA approval and then translating the Nippon Shinyaku partnership into durable royalty and milestone income.
Competitors
Capricor does not compete head-on with a single rival but sits alongside several categories of DMD-focused and cell/gene therapy companies:
- Exon-skipping therapies (mutation-specific): Sarepta Therapeutics' EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), and VYONDYS 53 (golodirsen); Nippon Shinyaku/NS Pharma's VILTEPSO (viltolarsen) — notably, Nippon Shinyaku is simultaneously Capricor's ex-U.S. commercialization partner and a competitor in the exon-skipping category.
- Gene therapy: Sarepta Therapeutics' ELEVIDYS (delandistrogene moxeparvovec-rokl), approved for DMD patients aged 4 and up, representing the most direct large-scale commercial competitor for DMD treatment dollars and physician mindshare.
- Cell and exosome therapy peers: other clinical-stage regenerative-medicine and exosome-delivery companies (e.g., Evox Therapeutics, Carmine Therapeutics) competing for capital, talent, and manufacturing capacity in the broader cell/exosome therapeutics space, though none currently target DMD with a comparable cardiac-focused cell therapy.
Deramiocel is positioned as complementary rather than substitutive: it targets inflammatory and fibrotic pathways affecting skeletal and cardiac muscle rather than the underlying dystrophin mutation, meaning it could in principle be used alongside exon-skipping or gene therapy rather than replacing them.
Competitive Position
Capricor's principal advantage is being first-in-class with a mechanism — an allogeneic cardiosphere-derived cell therapy — that addresses cardiac dysfunction in DMD, an area existing genetic-mutation therapies do not directly target. Positive Phase 3 HOPE-3 results (announced December 2025, with the primary endpoint reaching statistical significance at p=0.03 and key cardiac endpoints also significant) support the clinical case, and the Nippon Shinyaku partnership provides non-dilutive capital plus an experienced ex-U.S. commercial infrastructure, reducing the launch risk a smaller biotech would otherwise face alone. However, the position remains fragile: the company has zero approved products and zero product revenue, so its entire value rests on a single lead asset; the FDA has already pushed the PDUFA target action date from August 22 to November 22, 2026 after requesting a major amendment, introducing regulatory timeline risk; and the stock's sharp volatility following September 2026 clinical-data disclosures has triggered multiple securities class-action lawsuits alleging misrepresentation, adding legal overhang and reputational risk. DMD's small, well-defined patient population is a double-edged sword — it limits total addressable market size but also discourages new entrants and supports premium orphan-drug pricing if deramiocel is approved. Capricor's near-term trajectory depends almost entirely on FDA approval execution and, if cleared, its ability to convert the Nippon Shinyaku milestone and royalty structure into cash flow against larger, better-capitalized rivals like Sarepta.